Quintiles as 'Best CRO in Asia'

“This award reflects Quintiles’ ability to improve our customers’ probability of success by combining market knowledge with superior service,” - Ken Lee, M.D., Quintiles vice president and regional general manager for Southeast Asia


Quintiles as 'Best CRO in Asia'

Quintiles was named the "Best CRO in Asia" at the 2014 BioPharma Asia Industry Awards, the third time in the event's four-year history that Quintiles has received the honor. The award recognizes the contract research organization that has best demonstrated an ongoing commitment to improve clinical research in Asia and help customers succeed.

"For 20 years we've been helping our customers navigate Asia's complex and changing healthcare environment. It's wonderful to be acknowledged for our excellence in bringing knowledge and people together for a healthier world" expressed Mr Ken Lee, MD, Quintiles vice president and regional general manager for Southeast Asia, who accepted the award.

In the last two years, Quintiles has continued to expand its integrated services in Asia-Pacific, including, launching a late phase research offering, real world and late phase research, to help companies, governments and payers determine the value of new medicines in real-world use.

And also Significantly expanding its local CRO in China, Kun Tuo, which complements its global offering through Quintiles China. while adding anatomic pathology, genomics and flow cytometry testing capabilities to its central laboratories in Singapore, Beijing, Tokyo and India.

Mr Anand Tharmaratnam, MD, Quintiles senior vice president and head of Asia-Pacific, said, "I'd like to dedicate to this to our employees, whose excellence made it possible; to our valued customers; and to patients worldwide whose lives and quality of life depend on new and better medicines."

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email